[Myotonia with muscular weakness corrected by exercise. The therapeutic effect of mexiletine]
- PMID: 6677978
[Myotonia with muscular weakness corrected by exercise. The therapeutic effect of mexiletine]
Abstract
A case of generalized myotonia with autosomal recessive transmission related to Becker's type is reported. A muscular weakness improved by exercise was combined to myotonia. In addition to abundant myotonic discharges, electromyography showed alteration of the voluntary pattern during sustained contraction. The repetitive stimulation showed a marked decrement of the motor potential amplitude with high frequency stimulation. Carbamazepine (800 mg/day) and diphenylhydantoin (300 mg/day) were without effect while myotonia and muscular weakness were considerably and quickly improved by mexiletine (400 mg/day). Tests on ergometric bicycle allowed to quantify this improvement. The physiopathological mechanism of muscular weakness is considered as a depolarization block due to the cumulative depolarization which occurs during myotonic discharge. Most antimyotonic drugs belong to the group of local anesthetics. One of their characteristics is a blocking potency depending on the frequency of membrane activity. Their action is predominant on fibers with repetitive discharges; thus they block the myotonic discharge and prevent the membrane block due to cumulative depolarization. All local anesthetics do not have the same antimyotonic effect. The low molecular weight of mexiletine entails a faster time constant for the block recovery of the sodium channel. It follows that the drug block mainly depends on the frequency of membrane activity and this characteristic could explain the remarkable antimyotonic effect of mexiletine.
Similar articles
-
Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy.Muscle Nerve. 1994 Jul;17(7):763-8. doi: 10.1002/mus.880170710. Muscle Nerve. 1994. PMID: 8008003
-
Myotonia congenita--a cause of muscle weakness and stiffness.Nat Clin Pract Neurol. 2006 Jul;2(7):393-9; quiz following 399. doi: 10.1038/ncpneuro0239. Nat Clin Pract Neurol. 2006. PMID: 16932590
-
[Value of mexiletine in the treatment of Thomsen-Becker myotonia].Arch Fr Pediatr. 1986 Jan;43(1):49-50. Arch Fr Pediatr. 1986. PMID: 3707279 French.
-
Myotonia congenita.Semin Neurol. 1991 Sep;11(3):244-8. doi: 10.1055/s-2008-1041228. Semin Neurol. 1991. PMID: 1947487 Review.
-
[Myotonia congenital (Thomsen) and recessive generalized myotonia (Becker)].Nervenarzt. 1993 Dec;64(12):766-9. Nervenarzt. 1993. PMID: 8114977 Review. German.
Cited by
-
Repetitive nerve stimulation in the differential diagnosis of congenital myotonia.Ital J Neurol Sci. 1984 Dec;5(4):385-90. doi: 10.1007/BF02042621. Ital J Neurol Sci. 1984. PMID: 6530361
-
Drug Repurposing for Rare Diseases: A Role for Academia.Front Pharmacol. 2021 Oct 20;12:746987. doi: 10.3389/fphar.2021.746987. eCollection 2021. Front Pharmacol. 2021. PMID: 34744726 Free PMC article.
-
Drug treatment for myotonia.Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD004762. doi: 10.1002/14651858.CD004762.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2025 Apr 08;4:CD004762. doi: 10.1002/14651858.CD004762.pub3. PMID: 16437496 Free PMC article. Updated.
-
Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.Neurology. 2010 May 4;74(18):1441-8. doi: 10.1212/WNL.0b013e3181dc1a3a. Neurology. 2010. PMID: 20439846 Free PMC article. Clinical Trial.
-
Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel.BMC Neurol. 2021 Dec 1;21(1):467. doi: 10.1186/s12883-021-02491-3. BMC Neurol. 2021. PMID: 34852780 Free PMC article.